Development of Pyrimidinon Derivative Compounds from Methoxy Bis-Chalcone Analogs as Potential Anticancer Candidates
Abstract
Purpose of the study: This study aims to evaluate its bioactivity as a candidate anticancer compound through inhibition testing of dihydrofolate reductase enzyme activity.
Methodology: Organic synthesis methods through condensation and cyclization, reflux, recrystallization, preparative thin layer chromatography, Fisher John Melting Point Apparatus, ultraviolet visible spectrometer, nuclear magnetic resonance spectrometer, mass spectrometer, infrared spectrometer, centrifugation, in vitro dihydrofolate reductase enzyme inhibition test, probit analysis, methotrexate as a positive control, and evaluation of anticancer bioactivity.
Main Findings: The pyrimidinone derivative compound was successfully synthesized and confirmed through physical and spectroscopic characterization. The test results showed significant inhibitory activity against the dihydrofolate reductase enzyme. The synthesized compound had a fifty percent inhibitory concentration of 25.086 micrograms per milliliter, lower than the positive control, indicating better anticancer potential and high inhibitory effectiveness.
Novelty/Originality of this study: The novelty of this research lies in the synthesis of pyrimidinone derivatives based on bis-chalcone analogs containing methoxy groups, which have not been widely studied as anticancer candidates. This study provides new insights into the relationship between structure and biological activity, while also expanding the development of heterocyclic compounds as dihydrofolate reductase inhibitors for anticancer therapy.
References
M. S. Ghufran, P. Soni, and G. R. Duddukuri, “The Global Concern for Cancer Emergence and Its Prevention: A Systematic Unveiling of the Present Scenario,” in Bioprospecting of Tropical Medicinal Plants, Cham: Springer Nature Switzerland, 2023, pp. 1429–1455. doi: 10.1007/978-3-031-28780-0_60.
J. Zhou, W. Yang, and Q. Liu, “Cancer challenges worldwide and in China: preparing for the inevitable,” Sci. China Life Sci., vol. 65, no. 2, pp. 442–444, 2022, doi: 10.1007/s11427-021-2009-0.
H. Bahrami and M. Tafrihi, “Global trends of cancer: The role of diet, lifestyle, and environmental factors,” Cancer Innov., vol. 2, no. 4, pp. 290–301, Aug. 2023, doi: 10.1002/cai2.76.
S. Farina, A. Sabatelli, S. Boccia, and G. Scambia, “Environment, lifestyle, and cancer in women,” Int. J. Gynecol. Obstet., vol. 171, no. S1, pp. 138–146, 2025, doi: 10.1002/ijgo.70156.
R. Kaur, A. Bhardwaj, and S. Gupta, “Cancer treatment therapies: traditional to modern approaches to combat cancers,” Mol. Biol. Rep., vol. 50, no. 11, pp. 9663–9676, Nov. 2023, doi: 10.1007/s11033-023-08809-3.
P. Garg, J. Malhotra, P. Kulkarni, D. Horne, R. Salgia, and S. S. Singhal, “Emerging therapeutic strategies to overcome drug resistance in cancer cells,” Cancers (Basel)., vol. 16, no. 13, pp. 1–25, 2024, doi: 10.3390/cancers16132478.
E. Kabir and M. Uzzaman, “A review on biological and medicinal impact of heterocyclic compounds,” Results Chem., vol. 4, no. August, pp. 1–11, 2022, doi: 10.1016/j.rechem.2022.100606.
J. Baranwal, S. Kushwaha, S. Singh, and A. Jyoti, “A Review on the synthesis and pharmacological activity of heterocyclic compounds,” Curr. Phys. Chem., vol. 13, no. 1, pp. 2–19, Mar. 2023, doi: 10.2174/1877946813666221021144829.
G. H. Elgemeie, R. A. Azzam, W. A. Zaghary, M. A. Khedr, and G. E. Elsherif, “Medicinal chemistry of pyrazolopyrimidine scaffolds substituted with different heterocyclic nuclei,” Curr. Pharm. Des., vol. 28, no. 41, pp. 3374–3403, Nov. 2022, doi: 10.2174/1381612829666221102162000.
A. Alsharif, M. Allahyani, A. Aljuaid, A. A. Alsaiari, M. M. Almehmadi, and M. Asif, “Diverse pharmacological potential of various substituted pyrimidine derivatives,” Curr. Org. Chem., vol. 27, no. 20, pp. 1779–1798, Nov. 2023, doi: 10.2174/0113852728266665231101112129.
A. A. Ghoneim, A. F. El-Farargy, and R. B. Bakr, “Design, synthesis, molecular docking of novel substituted pyrimidinone derivatives as anticancer agents,” Polycycl. Aromat. Compd., vol. 42, no. 5, pp. 2538–2554, 2022, doi: 10.1080/10406638.2020.1837888.
W. A. Zaki et al., “Design, synthesis, in vitro, and in silico studies of new N5-substituted-pyrazolo[3,4-d]pyrimidinone derivatives as anticancer CDK2 inhibitors,” Pharmaceuticals, vol. 16, no. 11, pp. 1–13, 2023, doi: 10.3390/ph16111593.
G. E. S. Chaudhry, A. Md Akim, Y. Y. Sung, and T. M. T. Sifzizul, “Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics,” Front. Pharmacol., vol. 13, no. August, pp. 1–24, 2022, doi: 10.3389/fphar.2022.842376.
Y. Zhao et al., “Cancer metabolism: The role of ROS in DNA damage and induction of Apoptosis in cancer cells,” Metabolites, vol. 13, no. 7, pp. 1–25, 2023, doi: 10.3390/metabo13070796.
B. S. Manya et al., “Insights into the biological activities and substituent effects of pyrrole derivatives: The chemistry‐biology connection,” Chem. Biodivers., vol. 21, no. 8, pp. 1–9, Aug. 2024, doi: 10.1002/cbdv.202400534.
R. M. Keshk, Z. A. Salama, S. K. Elsaedany, E. M. A. ElRehim, and D. M. Beltagy, “Synthesis, antimicrobial, anti-inflammatory, antioxidant and cytotoxicity of new pyrimidine and pyrimidopyrimidine derivatives,” Sci. Rep., vol. 15, no. 1, pp. 1–16, Mar. 2025, doi: 10.1038/s41598-025-92066-w.
S. Chowdhary, Preeti, Shekhar, N. Gupta, R. Kumar, and V. Kumar, “Advances in chalcone-based anticancer therapy: mechanisms, preclinical advances, and future perspectives,” Expert Opin. Drug Discov., vol. 19, no. 12, pp. 1417–1437, Dec. 2024, doi: 10.1080/17460441.2024.2436908.
T. Constantinescu and A. G. Mihis, “Two important anticancer mechanisms of natural and synthetic chalcones,” Int. J. Mol. Sci., vol. 23, no. 19, pp. 1–26, 2022, doi: 10.3390/ijms231911595.
D. Pansare et al., “Synthesis and Biological Evaluation of Thiazoline, Thiophene and Thiazole Scaffolds,” in S-Heterocycles, Singapore: Springer Nature Singapore, 2024, pp. 105–133. doi: 10.1007/978-981-97-4308-7_3.
A. Ragab, S. A. Fouad, Y. A. Ammar, D. S. Aboul-Magd, and M. S. Abusaif, “Antibiofilm and anti-quorum-sensing activities of novel pyrazole and pyrazolo[1,5-a]pyrimidine derivatives as carbonic anhydrase I and II Inhibitors: Design, synthesis, radiosterilization, and molecular Docking Studies,” Antibiotics, vol. 12, no. 1, pp. 1–39, 2023, doi: 10.3390/antibiotics12010128.
S. Shah, R. Narang, V. J. Singh, G. Pilli, and S. K. Nayak, “A review on anticancer profile of flavonoids: Sources, chemistry, mechanisms, structure-activity relationship and anticancer activity,” Curr. Drug Res. Rev., vol. 15, no. 2, pp. 122–148, Jul. 2023, doi: 10.2174/2589977515666230120144852.
C. M. C. Andrés, J. M. Pérez de la Lastra, E. Bustamante Munguira, C. Andrés Juan, and E. Pérez-Lebeña, “Anticancer activity of metallodrugs and metallizing host defense peptides—current developments in structure-activity relationship,” Int. J. Mol. Sci., vol. 25, no. 13, pp. 1–45, 2024, doi: 10.3390/ijms25137314.
D. Muhammed Aziz, S. A. Hassan, A. A. M. Amin, M. N. Abdullah, K. Qurbani, and S. B. Aziz, “A synergistic investigation of azo-thiazole derivatives incorporating thiazole moieties: a comprehensive exploration of their synthesis, characterization, computational insights, solvatochromism, and multimodal biological activity assessment,” RSC Adv., vol. 13, no. 49, pp. 34534–34555, 2023, doi: 10.1039/d3ra06469g.
D. Tiwari et al., “A review on natural bioactive compounds of Taraxacum officinale Weber: a potential anticancer plant,” RPS Pharm. Pharmacol. Reports, vol. 3, no. 2, pp. 1–9, Apr. 2024, doi: 10.1093/rpsppr/rqae009.
P. Sivakumar, S. Bharanidharan, R. Rajamohan, B. Anandhan, T. Sumathi, and S. Kamatchi, “Synthesis and spectral characterization of 4-methylthiazole derivatives: DFT approach and biological activities,” New J. Chem., vol. 47, no. 34, pp. 16216–16227, 2023, doi: 10.1039/D3NJ03046F.
T. Kowalska and M. Sajewicz, “Thin-layer chromatography (TLC) in the screening of botanicals–Its versatile potential and selected applications,” Molecules, vol. 27, no. 19, pp. 1–23, 2022.
Y. Fukunaga, R. Ogawa, A. Homma, and T. Okada, “Thin layer chromatography‐freeze surface‐enhanced raman spectroscopy: A powerful tool for monitoring synthetic reactions,” Chem. – A Eur. J., vol. 29, no. 39, pp. 1–9, Jul. 2023, doi: 10.1002/chem.202300829.
I. Kekessie et al., “Process mass intensity (PMI): A holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis,” J. Org. Chem., vol. 89, no. 7, pp. 4261–4282, 2024, doi: 10.1021/acs.joc.3c01494.
K. Gach-Janczak, J. Drogosz-Stachowicz, A. Janecka, K. Wtorek, and M. Mirowski, “Historical perspective and current trends in anticancer drug development,” Chem. Eng. News, vol. 80, no. 23, pp. 1–18, 2002.
S. M. Tawfik, M. R. A. Abdollah, M. M. Elmazar, H. A. N. El-Fawal, and A. Abdelnaser, “Effects of metformin combined with antifolates on HepG2 cell metabolism and cellular proliferation,” Front. Oncol., vol. 12, no. February, pp. 1–17, 2022, doi: 10.3389/fonc.2022.828988.
F. O. Sefrji et al., “Synthetic approaches for novel fused pyrimidine derivatives: Design, structural characterization, antiviral, antitumor, and molecular docking evaluation,” Heliyon, vol. 10, no. 24, pp. 1–23, 2024, doi: 10.1016/j.heliyon.2024.e40903.
J. Y. Yoo, Y. Choi, H. Kim, and S. B. Park, “Revisiting pyrimidine-embedded molecular frameworks to probe the unexplored chemical space for protein protein interactions,” Acc. Chem. Res., vol. 57, no. 22, pp. 3254–3265, 2024, doi: 10.1021/acs.accounts.4c00452.
M. W. Islam et al., “A review on pyrimidine‐based derivatives: Synthesis and their biological application,” J. Heterocycl. Chem., vol. 61, no. 7, pp. 1159–1179, Jul. 2024, doi: 10.1002/jhet.4837.
N. Ayoub, A. Gedeon, and H. Munier-Lehmann, “A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis,” Front. Pharmacol., vol. 15, no. February, pp. 1–30, 2024, doi: 10.3389/fphar.2024.1329011.
R. Sehrawat et al., “Dihydrofolate reductase (DHFR) inhibitors: A comprehensive review,” Curr. Med. Chem., vol. 31, no. 7, pp. 799–824, Feb. 2024, doi: 10.2174/0929867330666230310091510.
H. Shamshad, R. Bakri, and A. Z. Mirza, Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases, vol. 49, no. 7. Springer Netherlands, 2022. doi: 10.1007/s11033-022-07266-8.
R. Rahmani et al., “FTIR, NMR and UV–Visible Spectral Investigations, Theoretical Calculations, Topological Analysis, Chemical Stablity, and Molecular Docking Study on Novel Bioactive Compound: The 5-(5-Nitro Furan-2-Ylmethylen), 3-N-(2-Methoxy Phenyl),2-N′- (2-Methoxyphenyl) Imino Thiazolidin-4-One,” Polycycl. Aromat. Compd., vol. 43, no. 5, pp. 4685–4706, 2023, doi: 10.1080/10406638.2022.2094971.
K. B. Gangurde, V. A. Adole, and D. S. Ghotekar, “Computational study: Synthesis, spectroscopic (UV–vis, IR, NMR), antibacterial, antifungal, antioxidant, molecular docking and ADME of new (E)-5-(1-(2-(4-(2,4-dichlorophenyl)thiazol-2-yl)hydrazineylidene)ethyl)-2,4-dimethylthiazole,” Results Chem., vol. 6, no. September, pp. 1–13, 2023, doi: 10.1016/j.rechem.2023.101093.
C. Qian, X. Li, J. Zhang, and Y. Wang, “Small molecular inhibitors that target ATM for drug discovery: Current research and potential prospective,” J. Med. Chem., vol. 67, no. 17, pp. 14742–14767, Sep. 2024, doi: 10.1021/acs.jmedchem.4c01064.
G. M. Nitulescu et al., “The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies,” Molecules, vol. 28, no. 14, pp. 1–32, 2023, doi: 10.3390/molecules28145359.
Copyright (c) 2026 Nia Tussholiha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and acknowledge that the Journal of Chemical Learning Innovation is the first publisher licensed under a Creative Commons Attribution 4.0 International License.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work.
.png)
.png)
